알파-4 베타-2 니코틴 수용체
Alpha-4 beta-2 nicotinic receptorα4β2 수용체라고도 하는 알파-4 베타-2 니코틴 수용체는 학습에 관여하는 니코틴 아세틸콜린 수용체의 일종으로 [1]α4와 β2 서브유닛으로 구성되어 있다.[2]뇌에 위치하며, 활성화는 주로+ Na와+ K 투과성 증가에 의해 시냅스 후와 사전 흥분 상태를 산출한다.[2]
이 수용체 아형의 자극은 성장 호르몬 분비와도 관련이 있다.CHRNA4 돌연변이 Ser248Pep은 평균보다 10cm(4인치) 짧고 비만이 되기 쉽다.[3]A2015년 리뷰는 그 뇌의α4β2 니코틴성 수용체의 자극 주의 공연에서 특정한 개선에 대한 책임이 있으면 니코틴성 수용체 특이한 가운데[4], 니코틴은 니코틴의 중독성이 필요한 적절한 중재하는은 생물학적 목표를 α4β2 수용체(ki=1 nM), 가장 높은 곳에 바인딩 관련성을 가지고 있다고 언급했다.관계.[5]
수용체는 다음 두 가지 확률로 존재한다.
- (α4)(2β2) 3수용체는 니코틴에 대한 민감도가 높고 Ca2+ 투과성이 낮다(HS 수용체)
- (α4)(3β2) 2수용체는 니코틴에 대한 민감도가 낮고 Ca2+ 투과성이 높다(LS 수용체)
구조
(α4)(2β2) 3수용체의 X선 구조는 2016년부터[6] 알려져 있으며, 서브유닛의 원형 α–β–β–α–β 순서를 밝히고 있다.
리간즈
고민자
- 3-브로모시티신
- 아세틸콜린
- 키티신
- 갈란타민
- 에피바티딘
- 에피복시딘[7]
- 니코틴
- A-84,543
- A-366,833
- ABT-418
- 아레콜린[8]
- 알티니라인
- 다이애닉라인
- 이스프로닉라인
- 포자니클라인
- 리바니클라인
- 테바니클라인
- TC-1827
- 바레니클라인
- 사제티딘 A: (α4)(2β2)에 대한 완전 작용제,3 (α4)에 대한 6% 효과(32[9]β2)
- N-(3-피리디닐) 교량 자전거 지름[10][11][12]
PAMs
반목자
- (----7-메틸-2-exo-[3-]-(6-[18F]플루오로피리딘-2-yl)-5'-피리디닐]-7-아자비시클로[2.2.1]헵탄[17]
- 2-142로-3-(4-148로-시닐)데스클로로포이바티딘[18]
- 코클라우린 - 넬럼보 누시페라산[19] 알칼로이드
- 메카밀라민[20]
- α-코노톡신
- PNU-120,596
- 부프로피온
- 디히드로-β-에르스로딘, 선택적[8]
- 아산화질소
- 이소플루란
- 1-(6-(R,S)-7--하이드록시크로마-2-yl)메틸아미노]헥시릴)-3-(S)-1-메틸피롤리딘-2-yl)피리디늄브로미드(복합 2)(헬로비발렌트 리간드: D2R 작용제 및 nACHR 길항제)[21]
NAMs
참고 항목
참조
- ^ Cordero-Erausquin, M; Marubio, LM; Klink, R; Changeux, JP (2000). "Nicotinic receptor function: new perspectives from knockout mice" (PDF). Trends Pharmacol. Sci. 21 (6): 211–7. doi:10.1016/S0165-6147(00)01489-9. PMID 10838608. Archived from the original (PDF) on 2014-05-15. Retrieved 2012-10-08.
- ^ a b Rang; Dale; Ritter; Moore (2003). Pharmacology (5th ed.). Churchill Livingstone. p. 138. ISBN 978-0-443-07145-4.
- ^ Fedi, M; Bach, LA; Berkovic, SF; Willoughby, JO; Scheffer, IE; Reutens, DC (2008). "Association of a nicotinic receptor mutation with reduced height and blunted physostigmine-stimulated growth hormone release". The Journal of Clinical Endocrinology and Metabolism. 93 (2): 634–7. doi:10.1210/jc.2007-1611. PMID 18042647.
- ^ Sarter M (August 2015). "Behavioral-cognitive targets for cholinergic enhancement". Current Opinion in Behavioral Sciences. 4: 22–26. doi:10.1016/j.cobeha.2015.01.004. PMC 5466806. PMID 28607947.
- ^ "Nicotine: Biological activity". IUPHAR/BPS Guide to Pharmacology. International Union of Basic and Clinical Pharmacology. Retrieved 7 February 2016.
Kis as follows; α2β4=9900nM [5], α3β2=14nM [1], α3β4=187nM [1], α4β2=1nM [4,6]. Due to the heterogeneity of nACh channels we have not tagged a primary drug target for nicotine, although the α4β2 is reported to be the predominant high affinity subtype in the brain which mediates nicotine addiction [2-3].
- ^ Morales-Perez CL, Noviello CM, Hibbs RE (2016). "X-ray structure of the human α4β2 nicotinic receptor". Nature. 538 (7625): 411–415. doi:10.1038/nature19785. PMC 5161573. PMID 27698419.
- ^ Dallanoce, Clelia; Matera, Carlo; Amici, Marco De; Rizzi, Luca; Pucci, Luca; Gotti, Cecilia; Clementi, Francesco; Micheli, Carlo De (2012-07-01). "The enantiomers of epiboxidine and of two related analogs: Synthesis and estimation of their binding affinity at α4β2 and α7 neuronal nicotinic acetylcholine receptors". Chirality. 24 (7): 543–551. doi:10.1002/chir.22052. ISSN 1520-636X. PMID 22566097.
- ^ a b Winger G (August 2021). "Nicotinic aspects of the discriminative stimulus effects of arecoline". Behavioural Pharmacology. doi:10.1097/FBP.0000000000000652. PMC 8446330. PMID 34417356.
- ^ Zwart, R.; Carbone, A. L.; Moroni, M.; Bermudez, I.; Mogg, A. J.; Folly, E. A.; Broad, L. M.; Williams, A. C.; Zhang, D.; Ding, C.; Heinz, B. A.; Sher, E. (2008). "Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors". Mol. Pharmacol. 73 (6): 1838–43. doi:10.1124/mol.108.045104. PMID 18367540. S2CID 24632914.
- ^ Bunnelle, William H.; Daanen, Jerome F.; Ryther, Keith B.; Schrimpf, Michael R.; Dart, Michael J.; Gelain, Arianna; Meyer, Michael D.; Frost, Jennifer M.; Anderson, David J.; Buckley, Michael; Curzon, Peter; Cao, Ying-Jun; Puttfarcken, Pamela; Searle, Xenia; Ji, Jianguo; Putman, C. Brent; Surowy, Carol; Toma, Lucio; Barlocco, Daniela (2007). "Structure-activity studies and analgesic efficacy of N-(3-pyridinyl)-bridged bicyclic diamines, exceptionally potent agonists at nicotinic acetylcholine receptors". J. Med. Chem. 50 (15): 3627–44. doi:10.1021/jm070018l. PMID 17585748.
- ^ Frost (Née Pac, Jennifer M.; Bunnelle, William H.; Tietje, Karin R.; Anderson, David J.; Rueter, Lynne E.; Curzon, Peter; Surowy, Carol S.; Ji, Jianquo; Daanen, Jerome F.; Kohlhaas, Kathy L.; Buckley, Michael J.; Henry, Rodger F.; Dyhring, Tino; Ahring, Philip K.; Meyer, Michael D. (2006). "Synthesis and structure-activity relationships of 3,8-diazabicyclo[4.2.0]octane ligands, potent nicotinic acetylcholine receptor agonists". J. Med. Chem. 49 (26): 7843–53. doi:10.1021/jm060846z. PMID 17181167.
- ^ Ji, Jianguo; Schrimpf, Michael R.; Sippy, Kevin B.; Bunnelle, William H.; Li, Tao; Anderson, David J.; Faltynek, Connie; Surowy, Carol S.; Dyhring, Tino; Ahring, Philip K.; Meyer, Michael D. (2007). "Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor selective agonists". J. Med. Chem. 50 (22): 5493–508. doi:10.1021/jm070755h. PMID 17929796.
- ^ Grupe, M; Jensen, AA; Ahring, PK; Christensen, JK; Grunnet, M (2013). "Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors". British Journal of Pharmacology. 168 (8): 2000–10. doi:10.1111/bph.12095. PMC 3623068. PMID 23278456.
- ^ Kim, Jin-Sung; Padnya, Anshul; Weltzin, Maegan; Edmonds, Brian W.; Schulte, Marvin K.; Glennon, Richard A. (2007). "Synthesis of desformylflustrabromine and its evaluation as an alpha4beta2 and alpha7 nACh receptor modulator". Bioorg. Med. Chem. Lett. 17 (17): 4855–60. doi:10.1016/j.bmcl.2007.06.047. PMC 3633077. PMID 17604168.
- ^ Albrecht, Brian K.; Berry, Virginia; Boezio, Alessandro A.; Cao, Lei; Clarkin, Kristie; Guo, Wenhong; Harmange, Jean-Christophe; Hierl, Markus; Huang, Liyue; Janosky, Brett; Knop, Johannes; Malmberg, Annika; McDermott, Jeff S.; Nguyen, Hung Q.; Springer, Stephanie K.; Waldon, Daniel; Woodin, Katrina; McDonough, Stefan I. (2008). "Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiators". Bioorg. Med. Chem. Lett. 18 (19): 5209–12. doi:10.1016/j.bmcl.2008.08.080. PMID 18789861.
- ^ Springer, Stephanie K.; Woodin, Katrina S.; Berry, Virginia; Boezio, Alessandro A.; Cao, Lei; Clarkin, Kristie; Harmange, Jean-Christophe; Hierl, Markus; Knop, Johannes; Malmberg, Annika B.; McDermott, Jeff S.; Nguyen, Hung Q.; Waldon, Daniel; Albrecht, Brian K.; McDonough, Stefan I. (2008). "Synthesis and activity of substituted carbamates as potentiators of the alpha4beta2 nicotinic acetylcholine receptor". Bioorg. Med. Chem. Lett. 18 (20): 5643–7. doi:10.1016/j.bmcl.2008.08.092. PMID 18805006.
- ^ Gao, Yongjun; Kuwabara, Hiroto; Spivak, Charles E.; Xiao, Yingxian; Kellar, Kenneth; Ravert, Hayden T.; Kumar, Anil; Alexander, Mohab; Hilton, John; Wong, Dean F.; Dannals, Robert F.; Horti, Andrew G. (2008). "Discovery of (−)-7-methyl-2-exo-[3'-(6-[18F]fluoropyridin-2-yl)-5'-pyridinyl]-7-azabicyclo[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties". J. Med. Chem. 51 (15): 4751–64. doi:10.1021/jm800323d. PMID 18605717.
- ^ Abdrakhmanova, G. R.; Damaj, M. I.; Carroll, F. I.; Martin, B. R. (2006). "2-Fluoro-3-(4-nitro-phenyl)deschloroepibatidine is a novel potent competitive antagonist of human neuronal alpha4beta2 nAChRs". Mol. Pharmacol. 69 (6): 1945–52. doi:10.1124/mol.105.021782. PMID 16505153. S2CID 96557182.
- ^ Kashiwada, Yoshiki; Aoshima, Akihiro; Ikeshiro, Yasumasa; Chen, Yuh-Pan; Furukawa, Hiroshi; Itoigawa, Masataka; Fujioka, Toshihiro; Mihashi, Kunihide; Cosentino, L. Mark; Morris-Natschke, Susan L.; Lee, Kuo-Hsiung (2005). "Anti-HIV benzylisoquinoline alkaloids and flavonoids from the leaves of Nelumbo nucifera, and structure–activity correlations with related alkaloids". Bioorganic & Medicinal Chemistry. 13 (2): 443–8. doi:10.1016/j.bmc.2004.10.020. PMID 15598565.
- ^ Fedorov, N. B.; Benson, L. C.; Graef, J.; Lippiello, P. M.; Bencherif, M. (February 2009). "Differential pharmacologies of mecamylamine enantiomers: positive allosteric modulation and noncompetitive inhibition". J. Pharmacol. Exp. Ther. 328 (2): 525–32. doi:10.1124/jpet.108.146910. PMID 18957576. S2CID 31849794.
- ^ Matera, Carlo; Pucci, Luca; Fiorentini, Chiara; Fucile, Sergio; Missale, Cristina; Grazioso, Giovanni; Clementi, Francesco; Zoli, Michele; De Amici, Marco (2015-08-28). "Bifunctional compounds targeting both D2 and non-α7 nACh receptors: Design, synthesis and pharmacological characterization". European Journal of Medicinal Chemistry. 101: 367–383. doi:10.1016/j.ejmech.2015.06.039. PMID 26164842.
- ^ Cesa LC, Higgins CA, Sando SR, Kuo DW, Levandoski MM (2012). "Specificity determinants of allosteric modulation in the neuronal nicotinic acetylcholine receptor: a fine line between inhibition and potentiation". Mol. Pharmacol. 81 (2): 239–49. doi:10.1124/mol.111.076059. PMC 3263947. PMID 22064677.